Patient-Reported outcomes and survivorship in radiation oncology: Overcoming the cons

Journal of Clinical Oncology

Volumn , Issue 26, 2014, Pages 2920-2927

  Siddiqui, Farzan ^a   Liu, Arthur K ^b   Watkins Bruner, Deborah ^c   Movsas, Benjamin ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c EMORY UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER PALLIATIVE THERAPY; CANCER SURVIVAL; CLINICAL DECISION MAKING; CLINICAL TRIAL (TOPIC); COMPARATIVE EFFECTIVENESS; FOLLOW UP; FOOD AND DRUG ADMINISTRATION; GOVERNMENT; HEALTH CARE POLICY; HUMAN; MEDICAL RESEARCH; ONCOLOGY; PATIENT REPORTED OUTCOME; PHYSICIAN; PRACTICE GUIDELINE; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; CANCER RADIOTHERAPY; CANCER SURVIVOR; FUNCTIONAL ASSESSMENT; INSURANCE; MEDICAL SOCIETY; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; RANDOMIZED CONTROLLED TRIAL (TOPIC); TREATMENT OUTCOME; NEOPLASMS; PROCEDURES; PSYCHOLOGY; RADIOTHERAPY; SELF REPORT; SURVIVAL RATE;

HUMANS; NEOPLASMS; RADIATION ONCOLOGY; RADIOTHERAPY; SELF REPORT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 84907015941     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2014.55.0707     Document Type: Review

References (93)

1. US Department of Health and Human Services, Food and Drug Administration: Guidance for Industry: Patient-Reported Outcome Measures-Use in Medical Product Development to Support Labeling Claims. http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
2. De Boer MF, Van den Borne B, Pruyn JF, et al: Psychosocial and physical correlates of survival and recurrence in patients with head and neck carcinoma: Results of a 6-year longitudinal study. Cancer 83:2567-2579, 1998
3. de Graeff A, de Leeuw JR, Ros WJ, et al: Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 37:332-339, 2001
4. Fang FM, Liu YT, Tang Y, et al: Quality of life as a survival predictor for patients with advanced head and neck carcinoma treated with radiotherapy. Cancer 100:425-432, 2004
5. Kaasa S, Mastekaasa A, Lund E: Prognostic factors for patients with inoperable non-small cell lung cancer, limited disease: The importance of patients' subjective experience of disease and psychosocial well-being. Radiother Oncol 15:235-242, 1989
6. Langendijk H, Aaronson NK, de Jong JM, et al: The prognostic impact of quality of life assessed with the EORTC QLQ-C30 in inoperable non-small cell lung carcinoma treated with radiotherapy. Radiother Oncol 55:19-25, 2000
7. Montazeri A, Milroy R, Hole D, et al: Quality of life in lung cancer patients: As an important prognostic factor. Lung Cancer 31:233-240, 2001
8. Siddiqui F, Pajak TF, Watkins-Bruner D, et al: Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: A Radiation Therapy Oncology Group analysis. Int J Radiat Oncol Biol Phys 70:353-360, 2008
9. Movsas B, Moughan J, Sarna L, et al: Quality of life supersedes the classic prognosticators for long-term survival in locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. J Clin Oncol 27:5816-5822, 2009
10. Giese-Davis J, Collie K, Rancourt KM, et al: Decrease in depression symptoms is associated with longer survival in patients with metastatic breast cancer: A secondary analysis. J Clin Oncol 29:413-420, 2011
11. Bjordal K, Kaasa S: Psychological distress in head and neck cancer patients 7-11 years after curative treatment. Br J Cancer 71:592-597, 1995
12. Langendijk JA, Doornaert P, Verdonck-de Leeuw IM, et al: Impact of late treatment-related toxicity on quality of life among patients with head and neck cancer treated with radiotherapy. J Clin Oncol 26:3770-3776, 2008
13. Johnson JR, Temple R: Food and Drug Administration requirements for approval of new anticancer drugs. Cancer Treat Rep 69:1155-1159, 1985
14. Johnson JR, Ning YM, Farrell A, et al: Accelerated approval of oncology products: The Food and Drug Administration experience. J Natl Cancer Inst 103:636-644, 2011
15. Ahmed S, Berzon RA, Revicki DA, et al: The use of patient-reported outcomes (PRO) within comparative effectiveness research: Implications for clinical practice and health care policy. Med Care 50:1060-1070, 2012
16. Reeve BB, Wyrwich KW, Wu AW, et al: ISOQOL recommends minimum standards for patient-reported outcome measures used in patient-centered outcomes and comparative effectiveness research. Qual Life Res 22:1889-1905, 2013
17. Institute of Medicine, Committee on Comparative Effectiveness Research Prioritization: Initial National Priorities for Comparative Effectiveness Research. Washington, DC, National Academies Press, 2009
18. Grosse SD: Assessing cost-effectiveness in healthcare: History of the $50,000 per QALY threshold. Expert Rev Pharmacoecon Outcomes Res 8:165-178, 2008
19. Konski A, Sherman E, Krahn M, et al: Economic analysis of a phase III clinical trial evaluating the addition of total androgen suppression to radiation versus radiation alone for locally advanced prostate cancer (Radiation Therapy Oncology Group protocol 86-10). Int J Radiat Oncol Biol Phys 63:788- 794, 2005
20. Van Den Brink M, Van Den Hout WB, Stiggelbout AM, et al: Cost-utility analysis of preoperative radiotherapy in patients with rectal cancer undergoing total mesorectal excision: A study of the Dutch Colorectal Cancer Group. J Clin Oncol 22:244-253, 2004
21. van den Hout WB, van der Linden YM, Steenland E, et al: Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial. J Natl Cancer Inst 95:222-229, 2003
22. Kohler RE, Sheets NC, Wheeler SB, et al: Twoyear and lifetime cost-effectiveness of intensity modulated radiation therapy versus 3-dimensional conformal radiation therapy for head-and-neck cancer. Int J Radiat Oncol Biol Phys 87:683-689, 2013
23. Mailhot Vega RB, Kim J, Bussiére M, et al: Cost effectiveness of proton therapy compared with photon therapy in the management of pediatric medulloblastoma. Cancer 119:4299-4307, 2013
24. Sloan JA, Sargent DJ, Novotny PJ, et al: Calibration of quality-adjusted life years for oncology clinical trials. J Pain Symptom Manage 10.1016/ j.jpainsymman.2013.07.016 [epub ahead of print November 15, 2013]
25. Sarna L, Swann S, Langer C, et al: Clinically meaningful differences in patient-reported outcomes with amifostine in combination with chemoradiation for locally advanced non-small-cell lung cancer: An analysis of RTOG 9801. Int J Radiat Oncol Biol Phys 72:1378-1384, 2008
26. Slevin ML, Plant H, Lynch D, et al: Who should measure quality of life, the doctor or the patient? Br J Cancer 57:109-112, 1988
27. Watkins-Bruner D, Scott C, Lawton C, et al: RTOG's first quality of life study: RTOG 90-20-A phase II trial of external beam radiation with etanidazole for locally advanced prostate cancer. Int J Radiat Oncol Biol Phys 33:901-906, 1995
28. Sonn GA, Sadetsky N, Presti JC, et al: Differing perceptions of quality of life in patients with prostate cancer and their doctors. J Urol 189:S59- S65, 2013
29. Sommers BD, Beard CJ, D'Amico AV, et al: Predictors of patient preferences and treatment choices for localized prostate cancer. Cancer 113: 2058-2067, 2008
30. Stiggelbout AM, de Haes JC: Patient preference for cancer therapy: An overview of measurement approaches. J Clin Oncol 19:220-230, 2001
31. Detmar SB, Aaronson NK, Wever LD, et al: How are you feeling? Who wants to know? Patients' and oncologists' preferences for discussing healthrelated quality-of-life issues. J Clin Oncol 18:3295- 3301, 2000
32. Detmar SB, Muller MJ, Schornagel JH, et al: Health-related quality-of-life assessments and patientphysician communication: A randomized controlled trial. JAMA 288:3027-3034, 2002
33. Velikova G, Booth L, Smith AB, et al: Measuring quality of life in routine oncology practice improves communication and patient well-being: A randomized controlled trial. J Clin Oncol 22:714-724, 2004
34. Testa MA, Simonson DC: Assessment of quality-of-life outcomes. N Engl J Med 334:835-840, 1996
35. Gotay CC, Korn EL, McCabe MS, et al: Quality-of-life assessment in cancer treatment protocols: Research issues in protocol development. J Natl Cancer Inst 84:575-579, 1992
36. Gelber RD, Gelber S: Quality-of-life assessment in clinical trials. Cancer Treat Res 75:225-246, 1995
37. Cella DF, Tulsky DS, Gray G, et al: The Functional Assessment of Cancer Therapy scale: Development and validation of the general measure. J Clin Oncol 11:570-579, 1993
38. Aaronson NK, Ahmedzai S, Bergman B, et al: The European Organization for Research and Treatment of Cancer QLQ-C30: A quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85:365-376, 1993
39. Stewart AL, Ware JE Jr: Measuring Functioning and Well-Being: The Medical Outcomes Study Approach. Durham, NC, Duke University Press, 1992
40. McHorney CA, Ware JE Jr, Lu JF, et al: The MOS 36-item Short-Form Health Survey (SF-36): III. Tests of data quality, scaling assumptions, and reliability across diverse patient groups. Med Care 32:40-66, 1994
41. McHorney CA, Ware JE Jr, Raczek AE: The MOS 36-Item Short-Form Health Survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care 31:247-263, 1993
42. Ware JE Jr, Sherbourne CD: The MOS 36- item short-form health survey (SF-36): I. Conceptual framework and item selection. Med Care 30:473- 483, 1992
43. Brady MJ, Cella DF, Mo F, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument. J Clin Oncol 15:974-986, 1997
44. Cella DF, Bonomi AE, Lloyd SR, et al: Reliability and validity of the Functional Assessment of Cancer Therapy-Lung (FACT-L) quality of life instrument. Lung Cancer 12:199-220, 1995
45. Osoba D, Aaronson NK, Muller M, et al: The development and psychometric validation of a brain cancer quality-of-life questionnaire for use in combination with general cancer-specific questionnaires. Qual Life Res 5:139-150, 1996
46. Department of Health and Human Services, National Institutes of Health: PROMIS: Dynamic Tools to Measure Health Outcomes From the Patient Perspective. www.nihpromis.org
47. Mapi Research Trust: PROQOLID: Patientreported outcome and quality of life instruments database. www.proqolid.org
48. National Cancer Institute, American College of Radiology: Radiation Therapy Oncology Group (RTOG) QOL/PRO library. http://www.rtog.org/Researchers/QOLPROMaterials.aspx
49. The Patient Reported Outcomes Measurement Information System (PROMIS): A Walk Through the First Four Years. http://www.nihpromis.org/Documents/PROMIS-The-First-Four-Years.pdf
50. Cella D, Yount S, Rothrock N, et al: The Patient-Reported Outcomes Measurement Information System (PROMIS): Progress of an NIH Roadmap cooperative group during its first two years. Med Care 45:S3-S11, 2007
51. National Cancer Institute, Applied Research, Cancer Control and Population Sciences: Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). http://appliedresearch.cancer.gov/tools/pro-ctcae.html
52. Calvert M, Blazeby J, Altman DG, et al: Reporting of patient-reported outcomes in randomized trials: The CONSORT PRO extension. JAMA 309: 814-822, 2013
53. Calvert M, Brundage M, Jacobsen PB, et al: The CONSORT Patient-Reported Outcome (PRO) extension: Implications for clinical trials and practice. Health Qual Life Outcomes 11:184, 2013
54. Wyrwich KW, Bullinger M, Aaronson N, et al: Estimating clinically significant differences in quality of life outcomes. Qual Life Res 14:285-295, 2005
55. Guyatt GH, Osoba D, Wu AW, et al: Methods to explain the clinical significance of health status measures. Mayo Clin Proc 77:371-383, 2002
56. Osoba D, Rodrigues G, Myles J, et al: Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16:139-144, 1998
57. Lydick E, Epstein RS: Interpretation of quality of life changes. Qual Life Res 2:221-226, 1993
58. Movsas B: Quality of life in oncology trials: A clinical guide. Semin Radiat Oncol 13:235-247, 2003
59. Siddiqui F, Kachnic LA, Movsas B: Quality-oflife outcomes in oncology. Hematol Oncol Clin North Am 20:165-185, 2006
60. Cohen J: Statistical Power Analysis for the Behavioral Sciences (ed 2). Hillsdale, NJ, L. Erlbaum Associates, 1988
61. Fayers PM, Curran D, Machin D: Incomplete quality of life data in randomized trials: Missing items. Stat Med 17:679-696, 1998
62. Curran D, Molenberghs G, Fayers PM, et al: Incomplete quality of life data in randomized trials: Missing forms. Stat Med 17:697-709, 1998
63. Troxel AB, Fairclough DL, Curran D, et al: Statistical analysis of quality of life with missing data in cancer clinical trials. Stat Med 17:653-666, 1998
64. Movsas B, Hunt D, Watkins-Bruner D, et al: Can electronic web-based technology improve quality of life data collection? Analysis of Radiation Therapy Oncology Group 0828. Pract Radiat Oncol 4:187-191, 2014
65. Scott CB, Stetz J, Bruner DW, et al: Radiation Therapy Oncology Group quality of life assessment: Design, analysis, and data management issues. Qual Life Res 3:199-206, 1994
66. Hartsell WF, Scott CB, Bruner DW, et al: Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases. J Natl Cancer Inst 97:798-804, 2005
67. Konski AA, Winter K, Cole BF, et al: Qualityadjusted survival analysis of Radiation Therapy Oncology Group (RTOG) 90-03: Phase III randomized study comparing altered fractionation to standard fractionation radiotherapy for locally advanced head and neck squamous cell carcinoma. Head Neck 31:207-212, 2009
68. Lutz S, Berk L, Chang E, et al: Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. Int J Radiat Oncol Biol Phys 79:965-976, 2011
69. Gore EM, Bae K, Wong SJ, et al: Phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small- cell lung cancer: Primary analysis of Radiation Therapy Oncology Group study RTOG 0214. J Clin Oncol 29:272-278, 2011
70. Sun A, Bae K, Gore EM, et al: Phase III trial of prophylactic cranial irradiation compared with observation in patients with locally advanced non-smallcell lung cancer: Neurocognitive and quality-of-life analysis. J Clin Oncol 29:279-286, 2011
71. Gondi V, Paulus R, Bruner DW, et al: Decline in tested and self-reported cognitive functioning after prophylactic cranial irradiation for lung cancer: Pooled secondary analysis of Radiation Therapy Oncology Group randomized trials 0212 and 0214. Int J Radiat Oncol Biol Phys 86:656-664, 2013
72. Siegel R, DeSantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin 62:220-241, 2012
73. McCabe MS, Bhatia S, Oeffinger KC, et al: American Society of Clinical Oncology statement: Achieving high-quality cancer survivorship care. J Clin Oncol 31:631-640, 2013
74. St. Jude Children's Research Hospital: Childhood Cancer Survivor Study (CCSS). ccss.stjude.org
75. Oeffinger KC, Mertens AC, Sklar CA, et al: Chronic health conditions in adult survivors of childhood cancer. N Engl J Med 355:1572-1582, 2006
76. Huang IC, Brinkman TM, Kenzik K, et al: Association between the prevalence of symptoms and health-related quality of life in adult survivors of childhood cancer: A report from the St Jude Lifetime Cohort study. J Clin Oncol 31:4242-4251, 2013
77. Zeltzer LK, Recklitis C, Buchbinder D, et al: Psychological status in childhood cancer survivors: A report from the Childhood Cancer Survivor Study. J Clin Oncol 27:2396-2404, 2009
78. Weaver KE, Forsythe LP, Reeve BB, et al: Mental and physical health-related quality of life among U.S. cancer survivors: Population estimates from the 2010 National Health Interview Survey. Cancer Epidemiol Biomarkers Prev 21:2108-2117, 2012
79. Smith SK, Mayer DK, Zimmerman S, et al: Quality of life among long-term survivors of non- Hodgkin lymphoma: A follow-up study. J Clin Oncol 31:272-279, 2013
80. Hsu T, Ennis M, Hood N, et al: Quality of life in long-term breast cancer survivors. J Clin Oncol 31:3540-3548, 2013
81. Children's Oncology Group: Long-Term Follow-Up Guidelines for Survivors of Childhood, Adolescent, and Young Adult Cancers, Version 3.0. www.survivorshipguidelines.org
82. National Comprehensive Cancer Network: Home page. Network. http://www.nccn.org/professionals/physician-gls/pdf/hodgkins.pdf
83. Institute of Medicine: From Cancer Patient to Cancer Survivor: Lost in Transition, 2005. www.iom.edu/Reports/2005/From-Cancer-Patient-to-Cancer-Survivor-Lost-in-Transition.aspx
84. Eshelman-Kent D, Kinahan KE, Hobbie W, et al: Cancer survivorship practices, services, and delivery: A report from the Children's Oncology Group (COG) nursing discipline, adolescent/young adult, and late effects committees. J Cancer Surviv 5:345-357, 2011
85. Earle CC, Ganz PA: Cancer survivorship care: Don't let the perfect be the enemy of the good. J Clin Oncol 30:3764-3768, 2012
86. Virgo KS, Lerro CC, Klabunde CN, et al: Barriers to breast and colorectal cancer survivorship care: Perceptions of primary care physicians and medical oncologists in the United States. J Clin Oncol 31: 2322-2336, 2013
87. Institute of Medicine: Crossing the Quality Chasm: A New Health System for the 21st Century, 2001. www.iom.edu/Reports/2001/Crossing-the-Quality-Chasm-A-New-Health-System-for-the-21st-Century.aspx
88. Cheung WY, Neville BA, Cameron DB, et al: Comparisons of patient and physician expectations for cancer survivorship care. J Clin Oncol 27:2489- 2495, 2009
89. Arora NK, Jensen RE, Sulayman N, et al: Patient-physician communication about healthrelated quality-of-life problems: Are non-Hodgkin lymphoma survivors willing to talk? J Clin Oncol 31:3964-3970, 2013
90. Cheung WY, Neville BA, Earle CC: Associations among cancer survivorship discussions, patient and physician expectations, and receipt of follow-up care. J Clin Oncol 28:2577-2583, 2010
91. Bennett AV, Jensen RE, Basch E: Electronic patient-reported outcome systems in oncology clinical practice. CA Cancer J Clin 62:337-347, 2012
92. Sprangers MA, Sloan JA, Veenhoven R, et al: The establishment of the GENEQOL consortium to investigate the genetic disposition of patientreported quality-of-life outcomes. Twin Res Hum Genet 12:301-311, 2009
93. Schubert C, Hong S, Natarajan L, et al: The association between fatigue and inflammatory marker levels in cancer patients: A quantitative review. Brain Behav Immun 21:413-427, 2007